Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04341610
Other study ID # EudraCT number: 2020-001330-36
Secondary ID
Status Withdrawn
Phase Phase 1/Phase 2
First received
Last updated
Start date April 20, 2020
Est. completion date April 30, 2021

Study information

Verified date May 2020
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The emerging field of stem cell therapy holds promise of treating a variety of diseases. Especially the mesenchymal stromal cells from bone marrow or adipose tissue (ASCs) have proven their potential for regenerative therapy in patients with ischemic heart disease. Both of these cell types have putative immunomodulatory properties, as they have demonstrated their ability to evade recognition and actively suppress the immune system.

This knowledge is transferred into studies with COVID-19 patients having severe pulmonary dysfunction, to modify the virus induced immunological and inflammatory activity involved in the progression of disease often leading to prolonged ICU stay and in some occasion's death.

We will conduct a clinical trial in which patients with COVID-19 and severe pulmonary symptoms will be randomized to either placebo or treatment with allogeneic CSCC_ASCs from adipose tissue. The aim is to assess the impact of CSCC_ASCs on the activated immune system and clinical efficacy on pulmonary function.

The perspective is that this new information can be of pivotal importance and potentially be a paradigm shift for the clinical problems and severe outcome seen in some patients with severe COVID-19 and other severe diseases with Acute Respiratory Distress Syndrome.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 30, 2021
Est. primary completion date January 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Patients between 18-80 years

- Confirmed HCoV-19 infection

- Temperature above 38.0o C

- Pulmonary symptoms and signs, at least one of the following before clinical decision for intubation and respirator treatment:

1. Respiratory distress, RR = 30/min;

2. Oxygen saturation = 93% at rest state;

3. Arterial partial pressure of oxygen (PaO2) / Fraction of inspiration O2 (FiO2) = 300mmHg, 1mmHg=0.133kPa

- Pneumonia that is judged by chest radiograph or computed tomography

- In respirator and possible for treatment within the first 24 hours

Exclusion Criteria:

- Patients that have need for additional immunosuppressive treatment

- Patients with any past (within the past 3-5 years) or present malignancy (other than excised basal cell carcinoma).

- Co-Infection with other infectious agent.

- Females capable of becoming pregnant must have a negative pregnancy test prior to treatment. After inclusion, they must use contraceptives for 2 months following the given stem cell treatment. The pill, spiral, depot injection of progesterone, sub-dermal implantation, hormonal vaginal ring and transdermal patch regarded as safe contraceptives.

- Patients who are participating in other clinical trials.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Stem Cell Product
100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline

Locations

Country Name City State
Denmark 2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in clinical critical treatment index day 7 from randomization
Secondary Days of respirator treatment 3 months
Secondary Improvement of clinical symptoms including duration of fever and respiratory need 3 months
Secondary Mortality 3 months
Secondary Marker of Immunological function -CD4+ and CD8+ T cell count 3 months
Secondary C-reactive protein and leucocyte 3 months
Secondary Cytokine profile 3 months
Secondary Glomerular Filtration Rate 3 months
Secondary Duration of hospitalization 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Withdrawn NCT04842331 - PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT) Phase 2/Phase 3
Completed NCT02352168 - Airway Inflammation in Children With Allergic Rhinitis and Intervention N/A
Completed NCT00984945 - Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults Phase 1
Completed NCT01860898 - A Phase I Study of iPS Cell Generation From Patients With COPD N/A
Completed NCT00382408 - A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001 Phase 3
Completed NCT01442779 - Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT05907564 - Aventus Thrombectomy System Pulmonary Embolism Clinical Study N/A
Not yet recruiting NCT05534685 - Budesonia + Intratracheal Surfactant in Incidence of Bronchopulmonary Dysplasia N/A
Completed NCT03739112 - Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly Phase 3
Active, not recruiting NCT04170348 - Daily Vitamin D for Sickle-cell Respiratory Complications Phase 2
Completed NCT05056766 - How Does the Clinical and Paraclinical Efficacy of an Oral Appliance Evolved According to Propulsion: Control With Each mm of Advancement
Completed NCT01991587 - Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults Phase 1/Phase 2
Recruiting NCT05565872 - Effects of Supervision During a Community-based Exercise Intervention (Urban Training) in Patients With COPD N/A
Not yet recruiting NCT05592431 - Effect of Volume Guarantee-High Frequency Oscillatory Ventilation on Cerebral Blood Flow in Neonates N/A
Completed NCT03401463 - Assesment of the Endotracheal Tube Cuff Pressure Values in ICU Pateints Before and After Training Seminar N/A
Recruiting NCT02913365 - Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis N/A
Active, not recruiting NCT01055990 - Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients Phase 2
Completed NCT00743990 - Effect of Effect of a Medicated Topical Therapy , Petrolatum, and No Treatment on Nocturnal Cough N/A
Completed NCT02198391 - Study of Echinaforce Junior Tablets in Children With Acute Colds